Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NantKwest (NK) stocks in Canada

Learn how to easily invest in NantKwest stocks.

NantKwest is a biotechnology business based in the US. NantKwest stocks (NK.US) are listed on the NASDAQ and all prices are listed in US Dollars. NantKwest employs 171 staff and has a trailing 12-month revenue of around $111,000.

How to buy shares in NantKwest

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NantKwest stock price (NASDAQ:NK)

Use our graph to track the performance of NK stocks over time.

NantKwest shares at a glance

Information last updated 2022-01-02.
Latest market close$0.00
52-week range$17.76 - $46.82
50-day moving average $28.70
200-day moving average $14.19
Wall St. target price$18.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.89

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy NantKwest stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

NantKwest price performance over time

Historical closes compared with the close of $0 from 2022-01-14

1 week (2022-01-18) nan%
1 month (2021-12-25) nan%
3 months (2021-10-29) -100.00%
6 months (2021-07-29) -100.00%
1 year (2021-01-29) -100.00%
2 years (2020-01-29) -100.00%
3 years (2019-01-29) 1.08
5 years (2017-01-27) 5.37

Is NantKwest under- or over-valued?

Valuing NantKwest stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NantKwest's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NantKwest's PEG ratio

NantKwest's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NantKwest's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NantKwest financials

Revenue TTM $111,000
Gross profit TTM $111,000
Return on assets TTM -36.2%
Return on equity TTM -77.61%
Profit margin 0%
Book value $1.08
Market capitalisation $3.6 billion

TTM: trailing 12 months

NantKwest share dividends

We're not expecting NantKwest to pay a dividend over the next 12 months.

Have NantKwest's shares ever split?

NantKwest's shares were split on a 8:1 basis on 17 August 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 8 shares. This wouldn't directly have changed the overall worth of your NantKwest shares – just the quantity. However, indirectly, the new 87.5% lower share price could have impacted the market appetite for NantKwest shares which in turn could have impacted NantKwest's share price.

NantKwest share price volatility

Over the last 12 months, NantKwest's shares have ranged in value from as little as $17.76 up to $46.82. A popular way to gauge a stock's volatility is its "beta".

NK.US volatility(beta: 2.39)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantKwest's is 2.3862. This would suggest that NantKwest's shares are significantly more volatile than the average for this exchange and represent a higher risk.

NantKwest overview

NantKwest, Inc. , a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc.

NantKwest in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site